Tag: inter partes review

(cross-posted from IP Watchdog) I’ll be speaking on November 17, 2015 at IAM’s Patent Law and Policy event. (It looks to be a really interesting day.) My panel has the provocative title, “Death...

Kyle Bass has lost another one of his inter partes review petitions. (If you need reminding who Kyle Bass is, see here and here.) I'm on a panel this coming Tuesday (9/8/2015) with a couple of p...

I've written about [define term="inter partes review"] a number of times (e.g., here, here, and here) because it's an incredibly useful tool for dealing with bad patents. Now, Scott Graham and Lisa Sh...

Kyle Bass, the hedge fund manager who filed a number of inter partes review petitions against pharmaceutical companies, has struck terror into the shriveled hearts of the pharmaceutical industry. The ...

Here's a video I've done to explain why the pharmaceutical companies' campaign against inter partes review is disingenuous at best: You can read more about IPRs here. Note: There was a comment on T...

Note: This is Part 3 in a three-part series. If you're not comfortable with how inter partes review works, you may want to start with Part 1. If you are comfortable with IPRs, start with Part 2. Gut...

Note: This is Part 2 in a three-part series. If you're not comfortable with how inter partes review works, you may want to start with Part 1. The Complaints About Inter Partes Review (IPR) Some pate...

Note: This is Part 1 in a three-part series. If you're already comfortable with how inter partes review works, you may want to skip to Part 2. If you watched the Senate hearing last week, you heard a...